Skip to main content
Equibles
EPC logo

EPC · EDGEWELL PERSONAL CARE Co

Track EPC — free

Use EPC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EPC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$27.28 -1.46 (-5.08%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.26B
Shares
46.09M
Volume · Nov 13 634.09K Avg daily vol (3M) 537.22K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.28 Open$28.41 Day$27.20–29.07 52W close$15.91–29.66 Avg vol 30d514K Short int4.9M · 10.7% of shares · 10.9d Short vol62% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-K · Nov 13

Up next

Next earnings call
Feb 8, 2027 Est · unconfirmed · in 12 wks
Q4 2026 earnings call transcript
call held Nov 12, 2026
Play latest call

Latest documents

2026
Nov 13
Annual report 10-K FY2026, ended Sep 30
Feminine Care sale pays down debt amid higher organic sales

Edgewell closed the sale of Feminine Care to Essity Aktiebolag (publ) on February 2, 2026, receiving approximately $340 and using proceeds to repay debt. Fiscal 2026 net sales rose 1.8% to $1,996.5, while organic sales increased 0.3%.

Revenue $2B ▲ 1.8% Net loss $51.7M Diluted EPS -$1.12
Read from the MD&A section
3 source passages
On February 2, 2026, we closed the sale of our Feminine Care business to Essity Aktiebolag (publ) (“Essity”) and received proceeds of approximately $340 on a cash-free and debt-free basis. The decrease in interest expense was the result of lower borrowing levels on the Company’s U.S. revolving credit facility due to the paydown of the facility with the proceeds of the Feminine Care divestiture. During fiscal 2026, net sales were $1,996.5, an increase of $34.5, or 1.8%, including a $28.2 favorable impact due to currency movements. Organic net sales increased $6.3, or 0.3%. Open the document at this passage
Sep 23
Current report 8-K Events of Sep 17
Director or officer change, or executive pay

Edgewell Personal Care Company determined that LaTanya Langley will serve as Chief Administrative and Legal Officer and Corporate Secretary effective October 1, 2026, when she will no longer serve as Chief People Officer. Her compensation will not change.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.00B
Trailing 12 months
Net income (TTM)
−$51.70M
Trailing 12 months
Revenue growth YoY
+3.0%
Year over year
Operating margin
2.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$874.40M
Latest balance sheet
Dividend yield
2.2%
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+48.3%
Trailing year
Short interest
10.7%
Latest settlement · 10.9 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼15.1% $415.10M −$2.10M '25 Q1 ▼13.8% $516.60M $29.00M '25 Q2 ▼13.5% $560.40M $29.10M '25 Q3 ▲100.8% $469.90M −$30.60M '25 Q4* ▲1.9% $422.80M −$65.70M '26 Q1 ▲0.6% $519.50M −$10.60M '26 Q2 ▲1.7% $570.10M $13.70M '26 Q3 LATEST ▲3% $484.10M $10.90M '26 Q4*

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q4 FY26 earnings call · Nov 12, 2026
Q4 FY26

TL;DR. Fiscal 2026 closed with fourth-quarter organic net sales growth of 3.1%, gross margin expansion of more than 500 basis points, and strong Cremo and Hawaiian Tropic results, while full-year adjusted operating profit and operating cash flow declined and wet shave sales fell about 1%. Fiscal 2027 guidance calls for organic sales growth of 1% to 3%, approximately 70 basis points of adjusted operating margin expansion and adjusted EPS of $1.85 to $2.15, while absorbing inflation, wet-shave supply disruption, a delayed consolidation and approximately $55 million of pre-tax restructuring charges.

Bullish
  • + Fourth-quarter organic net sales increased 3.1%, gross margin expanded by more than 500 basis points, and adjusted EBITDA and adjusted earnings per share delivered meaningful growth. new
  • + Fiscal 2027 guidance calls for organic net sales growth of 1% to 3% in both North America and international. new
  • + Fiscal 2027 adjusted operating margin is expected to increase approximately 70 basis points. new
  • + Fiscal 2027 adjusted EPS is expected to be $1.85 to $2.15 per share, with approximately 3.5% growth at the midpoint. new
  • + Cremo grew more than 50% in the fourth quarter, marking its eighth consecutive quarter of growth above 20%. new
  • + Hawaiian Tropic delivered strong results supported by increased distribution, innovation and brand investment. new
Bearish
  • − Full-year adjusted operating profit decreased $11.7 million, or approximately 7%, and adjusted operating margin fell approximately 70 basis points. new
  • − Net cash provided by operating activities declined to approximately $50 million from approximately $118 million. new
  • − Full-year wet shave sales declined about 1% as private-label sales fell roughly 10% because of anticipated supply-chain issues. new
  • − Fourth-quarter gross margin fell slightly below expectations because of higher-than-anticipated inflation, including diesel freight and oil costs. new
  • − The wet-shave manufacturing consolidation timeline shifted about six months, with associated savings now expected to begin in fiscal 2028. new
  • − Edgewell expects approximately $55 million of pre-tax restructuring and related charges in fiscal 2027. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Weak Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg −2%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 83%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −2%
trailing
6-month return +56%
trailing
YTD return +60%
this year
Relative strength +55%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $28 › 200d $24 — 50d above 200d
Institutional flow Distributing
206 of 225 funds reported for Sep 30 · net -314.6K sh shares · +36 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.70% of shares out · ▲ +5.7% MoM · 10.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
225 holders — near 3-yr low, contrarian setup
Squeeze score 84
high risk · 0–100
Fundamentals
Weak
Revenue growth +2%
Y/Y
Gross margin 42%
contracting
EPS growth −311%
Y/Y
Free cash flow $-35.7M
Buyback $85.0M
remaining
Balance sheet $874.4M
net debt
Quant / Vol
risk profile
High
Volatility 44%
annualized · 1-yr
Max drawdown −33%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 6
Latest guidance · from the 8-K filed Nov 12, 2026
fiscal 2027
Reported net sales 0.4% – 2.4%
GAAP EPS $0.90 – $1.20
prior FY $-1.12 midpoint +193.8% Y/Y
Adjusted EPS $1.85 – $2.15
Adjusted EBITDA $250M – $270M
Other income, net $13M
Interest expense associated with debt $67M
Adjusted effective tax rate 24%
Capital expenditures 2.75% – 3.25%
Adjusted free cash flow $100M – $120M
full fiscal year
Pre-tax charges $55M
Fiscal 2027
Fiscal 2027 GAAP Net Income $42 – $57
Income tax provision $11 – $16
EBITDA $190 – $210
Fiscal 2027 Adjusted EBITDA $250 – $270
Previous outlook earlier release · from the Earnings Call filed Mar 31, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted gross margin · Q3 44% – 45%
A&P as a percent of net sales · Q3 15% – 16%
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
Adjusted EPS · Fiscal 26 $1.80 – $2.00
Adjusted EBITDA · Fiscal 26 $250M – $260M
Adjusted free cash flow excluding the impacts of FEMCARE divesti · Fiscal 26 $80M – $110M
Guided vs delivered · last 6 settled
GAAP EPS fiscal 2026
guided $0.55 – $0.95
$-1.12 Miss −249.3%
GAAP EPS fiscal 2025
guided $1.73
$0.53 Miss −69.4%
GAAP EPS fiscal 2024
guided $2.28
$1.97 Miss −13.6%
GAAP EPS fiscal 2023
guided $1.95 – $2.15
$2.21 Beat +7.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
83% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $28 › 200d $24 — 50d above 200d
Institutional flow Distributing
206 of 225 funds reported for Sep 30 · net -314.6K sh shares · +36 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.70% of shares out · ▲ +5.7% MoM · 10.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
225 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $16 Now $27 · 83% Range high $30
vs 200-day avg +12% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBIT from continuing operations non-GAAP $46M Three Months Ended June 30, 2026 filing —
Adjusted EBITDA non-GAAP $177.7M Nine Months Ended June 30, 2026 —
Adjusted EPS non-GAAP $0.72 Q3 FY2026 —
Adjusted gross margin non-GAAP 44.5% Three Months Ended June 30, 2026 filing —
Adjusted net earnings from continuing operations non-GAAP $33.5M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP Net (Loss) Income from Continuing Operations $12.3M
+$18.5M Restructuring and related costs
+$0.6M Sun Care reformulation costs
-$0.1M Commercial realignment
+$2.2M Other project and related costs
= Adjusted Net Earnings from Continuing Operations $33.5M
Adjusted operating income non-GAAP $53M Three Months Ended June 30, 2026 filing —
Net debt non-GAAP $882.1M As of June 30, 2026 —
Organic net sales non-GAAP 1.1% Q3 FY2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Household & Personal Products — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EPC
EDGEWELL PERSONAL CARE Co
this stock
$1.26B +60.0% +1.8% — 10.7%
PG
PROCTER & GAMBLE Co
 $393.56B +18.5% +3.3% 25.6 1.0%
UL
Unilever PLC
 $142.57B +1.2% — — 0.3%
CL
Colgate Palmolive Co
 $79.23B +26.1% +1.7% 38.9 2.3%
RBGLY
Reckitt Benckiser Group PLC
 $47.99B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
251
% held
116.3%
Reported
206 of 225
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
270
View
Short & Settlement
Short Interest Rising
Shares short
4.9M
Days to cover
10.9d
Change
+264.6K sh
View
Short Volume
Short vol %
62%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
754
Value
$20.9K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
34.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.0B
Net income (FY)
$-51.7M
EPS diluted
$-1.12
View
Buybacks
Authorized
$100.0M
Remaining
$85.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-K
Filed
Nov 13, 2026
This year
14

Edgewell closed the sale of Feminine Care to Essity Aktiebolag (publ) on February 2, 2026, receiving approximately $340 and using proceeds to repay debt. Fiscal 2026 net sales rose 1.8% to $1,996.5, while organic sales increased 0.3%.

View
Proposed Sales
Value
$692.6K
Shares
24.3K
Filed
May 13, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Edgewell Personal Care Announces…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
EPC -2.5% -2.3% +55.7% -4.5% +60.0%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.1% -1.1% +55.2% -4.3% +49.4%

Capital returns

Latest dividend
$0.15 / share · ex Sep 9, 2026
Declared · upcoming
$0.15 / share · ex Dec 3, 2026
Paid (TTM)
$0.60 / share · 4 payouts
Dividend yield (TTM, derived)
2.20%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$15.00M
Remaining
$85.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1096752 CUSIP 28035Q102 13F (30d) 199 filings 177 filers Visit website Investor relations